NCT07027423View on ClinicalTrials.gov

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

January 29, 2027

Study Completion Date

January 29, 2027

Conditions
Sarcoma, Soft-tissueSarcomaSarcoma,Soft TissueSarcomas
Interventions
DRUG

BOLD-100

BOLD-100 in combination with Doxorubicin (Escalation)

DRUG

Doxorubicin 75 mg/m^2

BOLD-100 in combination with Doxorubicin (Escalation)

DRUG

BOLD-100

BOLD-100 in combination with Doxorubicin (Expansion)

DRUG

Doxorubicin 75 mg/m^2

BOLD-100 in combination with Doxorubicin (Expansion)

Trial Locations (1)

M5G 1Z5

UHN- Princess Margaret Cancer Center, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER